U.S. Pharmaceutical Manufacturing and Supply Chain: 2025 Risks, Opportunities for Stakeholders

Start
The U.S. House of Representatives Committee on Energy and Commerce’s Subcommittee on Health held a recent hearing titled “Made in America: Strengthening Domestic Manufacturing and the Health Care Supply Chain.” The hearing assessed America’s reliance on foreign sources for drugs and active pharmaceutical ingredients, the need to stabilize and grow domestic drug manufacturing capabilities, and the overall fragility of the U.S. drug supply chain….
By: Holland & Knight LLP
Previous Story

Legal Considerations Concerning the End-of-Life Management of Solar, Wind, and Battery Technologies in the US

Next Story

U.S. Senate Passes the GENIUS Act – Stablecoin Legislation Moves to the House